The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival
F. Aubin et al., The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival, MELANOMA RE, 10(2), 2000, pp. 113-118
The presence of tyrosinase mRNA in the peripheral blood cells of melanoma p
atients has been recently studied as a possible marker of haematogenous dis
semination, However, considerable variations in the rates of detection have
been noted. We determined the presence of tyrosinase mRNA positive circula
ting cells using reverse transcriptase-polymerase chain reaction (RT-PCR) i
n 35 patients with stage I melanoma, two patients with stage II melanoma an
d two patients with stage III melanoma. Among the patients with stage I, 13
were tested before and after surgery (< 1 h). Twenty healthy subjects serv
ed as negative controls. Out of the melanoma patients, the tyrosinase gene
was expressed in three of the 52 samples tested. Tyrosinase mRNA was presen
t in the circulating cells of only one patient with stage I melanoma after
intra-congenital naevi resection. However, two other stage I patients devel
oped rapidly lethal metastasis within the following 6 months, despite the l
ack of detectable tyrosinase mRNA. None of stage II patients were positive
for the tyrosinase transcripts, while both patients with stage III melanoma
showed enzyme expression. Our results confirm those of previous studies, s
howing that a small proportion of stage I melanoma patients have tyrosinase
-positive circulating cells. Moreover, the lack of tyrosinase mRNA detectio
n in the blood does not necessarily exclude metastatic progression. Therefo
re, this study indicates that the detection of tyrosinase mRNA-positive cir
culating cells by RT-PCR is not a predictive biomarker of a metastasis risk
in patients with stage I melanoma. (C) 2000 Lippincott Williams & Wilkins.